The mission of the UNT Health Science Center Technology Transfer & Commercialization Office is, by acting as a service provider, to assist UNTHSC, its researchers, and its community partners with the development and promotion of biomedical innovations.

Lilly Open Innovation Drug Discovery Program

The UNT Health Science Center is now authorized to participate in the Lilly Open Innovation Drug Discovery program. The Open Innovation Drug Discovery program is a unique opportunity for investigators from external institutions to submit proprietary compounds for potential screening in Lilly's state-of-the-art internal assays. This highly collaborative process is enabled by a web-based application that facilitates efficient transfer of information between Lilly and the investigator. UNT Health Science Center researchers can obtain a program registration code by contacting the UNT Health Science Center Technology Transfer & Commercialization Office by email: techtransfer@unthsc.edu or by phone: (817) 735-5147.

More information about the program can be learned at: https://openinnovation.lilly.com

Participation in the Lilly Open Innovation Drug Discovery program helps institutions in many different fronts:

• Lilly provides no-cost access to internal assay panel for external investigators in therapeutic areas of strategic interest
• Screening panel includes phenotypic disease-relevant assays (PD2) as well as selected target-based assays (TargetD2)
• Use of Lilly state-of-the-art computational tools for structure design available to participants
• Confidential compound submission via web-based interface
• Full data report provided to investigator
• Promising findings can serve as basis for a collaboration agreement
• Participants may have the additional option to participate in the Lilly TB Drug Discovery Initiative
• The investigator/institution retains IP rights to the molecule
• At all times, the investigator and institution maintain complete control of the decision to move to the next step in the process if an opportunity is presented

The Open Innovation Drug Discovery Screening Panel available to authorized users is comprised of both phenotypic and target-based assay modules. Each assay module is composed of a primary screening assay, followed by relevant secondary biochemical and cellular follow-up assays which further define the compound’s activity profile and early potential for further optimization. The results from the primary assay in each screening module will determine whether the compound is run through the secondary assay screens and beyond. Any compound submitted and accepted will be evaluated in at least all of the primary assay screens, and all the data generated will be returned to the investigator via this website.